Sedum aizoon L.: a review of its history, traditional uses, nutritional value, botany, phytochemistry, pharmacology, toxicology, and quality control.

In China, Russia, Mongolia, Japan, North Korea, and Mexico, Sedum aizoon L. (S. aizoon) is used as an edible plant. Up to now, over 234 metabolites, including phenolic acids, flavonoids, triterpenes, phytosterols, and alkaloids, among others, have been identified. In addition to its antioxidant, anti-inflammatory, anti-fatigue, antimicrobial, anti-cancer, and hemostatic activities, S. aizoon is used for the treatment of cardiovascular disease. This paper provides an overview of the history, botany, nutritional value, traditional use, phytochemistry, pharmacology, toxicology, and quality control of S. aizoon.

Impatiens balsamina: An updated review on the ethnobotanical uses, phytochemistry, and pharmacological activity.

ETHNOPHARMACOLOGICAL RELEVANCE: Impatiens balsamina is an annual herb of the Balsaminaceae family, which is cultivated extensively in Asia as an ornamental plant. Notably, as a folk medicine, I. balsamina has been long prescribed for the treatment of rheumatism, isthmus, generalized pain, fractures, inflammation of the nails, scurvy, carbuncles, dysentery, bruises, foot diseases, etc. AIM OF THE STUDY: The paper overviews comprehensive information on ethnobotanical uses, phytochemistry, pharmacological activity, and toxicity of I. balsamina, aiming at laying a sturdy foundation for further development of I. balsamina. MATERIALS AND METHODS: Research information was acquired through electronic databases such as Web of Science, PubMed, SciFinder, ScienceDirect, Google Scholar, and CNKI with the keyword "Impatiens balsamina ". RESULTS: Briefly, more than 307 natural compounds have been separated and identified from various medicinal parts of I. balsamina, which are classified into diverse groups, like flavonoids, naphthoquinones, coumarins, terpenoids, sterols, phenols, fatty acids and their ester, naphthalene derivatives, nitrogen-containing compounds, polysaccharides, and other compounds. In particular, 2-methoxy-1,4-naphthoquinone, one of the naphthoquinones, is the predominant and most representative component. Moreover, I. balsamina furnishes numerous and complicated pharmacological activities, including antimicrobial, antiallergic, antipruritic, antitumor, antioxidant, anti-inflammatory, immunomodulatory, anti-hepatic fibrosis, insecticidal, and anthelmintic as well as enzyme-inhibiting activities, etc. Toxicological studies have shown that the hexane extract of the stems and leaves was less toxic, and the hydroalcoholic extract of stems was more toxic. CONCLUSIONS: The paper contributes to updating the ethnobotanical uses, phytochemistry, pharmacological activity, and toxicity of I. balsamina, which offer abundant information for future investigations and applications of I. balsamina.

Persistent Facial Flushing in a Patient with Telangiectasia Macularis Eruptiva Perstans: An Unusual but Should Emphasized Clinical Finding.

Facial flushing is one of the common conditions in dermatology, which affects the aesthetic of patients to a great extent, and even leads to psychological and economic burdens. The most common causes of facial flushing are often inflammatory skin diseases such as rosacea, contact dermatitis, and others, but the facial flushing as a sign can also be the cutaneous manifestation of systemic disease. Telangiectasia macularis eruptiva perstans (TMEP) is a rare disease associated with mast cells. Here, we describe an unusual clinical finding with persistent facial flushing in a patient with TMEP.

The traditional uses, phytochemistry and pharmacology of Abrus precatorius L.: A comprehensive review.

ETHNOPHARMACOLOGICAL RELEVANCE: Abrus precatorius L. (AP) is a folk medicine with a long-term medicinal history worldwide, which is extensively applied to various ailments, such as bronchitis, jaundice, hepatitis, contraception, tumor, abortion, malaria, etc. Meanwhile, its leaves are also served as tea in China, and its roots are employed as a substitute for Glycyrrhiza uralensis or as a raw material for the extraction of glycyrrhizin in India. Thus, AP is considered to be a plant with dual values of medicine and economy as well as its chemical composition and biological activity, which are of growing interest to the scientific community. AIM OF REVIEW: In the review, the traditional application, botany, chemical constituents, pharmacological activities, and toxicity are comprehensively and systematically summarized. MATERIALS AND METHODS: An extensive database retrieval was conducted to gather the specific information about AP from 1871 to 2022 using online bibliographic databases Web of Science, PubMed, SciFinder, Google Scholar, CNKI, and Baidu Scholar. The search terms comprise the keywords "Abrus precatorius", "phytochemistry", "pharmacological activity", "toxicity" and "traditional application" as a combination. RESULTS: To date, AP is traditionally used to treat various diseases, including sore throat, cough, bronchitis, jaundice, hepatitis, abdominal pain, contraception, tumor, abortion, malaria, and so on. More than 166 chemical compounds have been identified from AP, which primarily cover flavonoids, phenolics, terpenoids, steroids, alkaloids, organic acids, esters, proteins, polysaccharides, and so on. A wide range of in vitro and in vivo pharmacological functions of AP have been reported, such as antitumor, antimicrobial, insecticidal, antiprotozoal, antiparasitic, anti-inflammatory, antioxidant, immunomodulatory, antifertility, antidiabetic, other pharmacological activities. The crushed seeds in powder or paste form were comparatively toxic to humans and animals by oral administration. Interestingly, the methanolic extracts were non-toxic to adult Wistar albino rats at various doses (200 and 400 mg/kg) daily. CONCLUSIONS: The review focuses on the traditional application, botany, phytochemistry, pharmacological activities, and toxicity of AP, which offers a valuable context for researchers on the current research status and a reference for further research and applications of this medicinal plant.

Mechanism of METTL3-mediated m6A modification in depression-induced cognitive deficits.

Depressive disorder (DD) is associated with N6-methyladenosine (m6A) hypermethylation. This study sought to explore the molecular mechanism of Methyltransferase-like 3 (METTL3) in cognitive deficits of chronic unpredictable mild stress (CUMS)-treated rats and provide novel targets for DD treatment. A DD rat model was established via CUMS treatment. Cognitive deficits were assessed via body weighing and behavioral tests. METTL3, microRNA (miR)-221-3p, pri-miR-221, GRB2-associated binding protein 1 (Gab1) expressions in hippocampal tissues were detected via RT-qPCR and Western blotting. m6A, DiGeorge syndrome critical region gene 8 (DGCR8)-bound pri-miR-221 and pri-miR-221 m6A levels were measured. The binding relationship between miR-221-3p and Gab1 was testified by dual-luciferase and RNA pull-down assays. Rescue experiments were designed to confirm the role of miR-221-3p and Gab1. METTL3 was highly expressed in CUMS rats, and silencing METTL3 attenuated cognitive deficits of CUMS rats. METTL3-mediated m6A modification facilitated processing and maturation of pri-miR-221 via DGCR8 to upregulate miR-221-3p. miR-221-3p targeted Gab1. miR-221-3p overexpression or Gab1 downregulation reversed the role of silencing METTL3 in CUMS rats. Overall, METTL3-mediated m6A modification facilitated processing and maturation of pri-miR-221 to upregulate miR-221-3p and then inhibit Gab1, thereby aggravating cognitive deficits of CUMS rats.

Suppression of lncRNA-ATB prevents amyloid-ß-induced neurotoxicity in PC12 cells via regulating miR-200/ZNF217 axis.

OBJECTIVE: Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive cognitive decline with loss of memory. The objective of this study was to investigate the role and regulatory mechanism of lncRNA-ATB in regulating amyloid-ß-induced neurotoxicity in neuronal PC12 cells. MATERIAL AND METHODS: The expression levels of lncRNA-ATB in cerebrospinal fluid (CSF) and serum of patients with Alzheimer's disease (AD) were determined. In addition, PC12 cells were incubated with 20 µM Aß25-35 to induce cell injury. The lncRNA-ATB expression in Aß25-35-treated PC12 cells was also determined. Moreover, the effects of lncRNA-ATB suppression on Aß25-35-induced PC12 cell injury were investigated by assessing cell viability, apoptosis, cytotoxicity, and oxidative stress (intracellular Ca2+ and ROS concentrations and JC-1 mitochondrial membrane potential). Moreover, the regulatory relationships between lncRNA-ATB and miR-200 were explored, as well as the targets of miR-200 were identified. RESULTS: The results showed that lncRNA-ATB was increased expressed in the CSF and serum of patients with AD. Aß25-35-induced injury in PC12 cells and increased the expression of lncRNA-ATB. Suppression of lncRNA-ATB alleviated Aß25-35-induced PC12 cell injury. Further studies showed that miR-200 was negatively regulated by lncRNA-ATB. Suppression of lncRNA-ATB alleviated Aß25-35 injury by regulation of miR-200. Moreover, miR-200 negatively regulated ZNF217 expression and ZNF217 was a target of miR-200. CONCLUSIONS: Our findings indicate that lncRNA-ATB is highly expressed in AD patients. Suppression of lncRNA-ATB may protect PC12 cells against Aß25-35-induced neurotoxicity via regulating miR-200/ZNF217 axis. LncRNA-ATB/miR-200/ZNF217 axis may provide a new insight for preventing AD.

Reproducibility of Variant Calls in Replicate Next Generation Sequencing Experiments.

Nucleotide alterations detected by next generation sequencing are not always true biological changes but could represent sequencing errors. Even highly accurate methods can yield substantial error rates when applied to millions of nucleotides. In this study, we examined the reproducibility of nucleotide variant calls in replicate sequencing experiments of the same genomic DNA. We performed targeted sequencing of all known human protein kinase genes (kinome) (~3.2 Mb) using the SOLiD v4 platform. Seventeen breast cancer samples were sequenced in duplicate (n=14) or triplicate (n=3) to assess concordance of all calls and single nucleotide variant (SNV) calls. The concordance rates over the entire sequenced region were >99.99%, while the concordance rates for SNVs were 54.3-75.5%. There was substantial variation in basic sequencing metrics from experiment to experiment. The type of nucleotide substitution and genomic location of the variant had little impact on concordance but concordance increased with coverage level, variant allele count (VAC), variant allele frequency (VAF), variant allele quality and p-value of SNV-call. The most important determinants of concordance were VAC and VAF. Even using the highest stringency of QC metrics the reproducibility of SNV calls was around 80% suggesting that erroneous variant calling can be as high as 20-40% in a single experiment. The sequence data have been deposited into the European Genome-phenome Archive (EGA) with accession number EGAS00001000826.